Acadia pharmaceuticals announces august 4, 2022 action date for resubmitted supplemental new drug application for nuplazid® (pimavanserin) for the treatment of alzheimer's disease psychosis

San diego--(business wire)--acadia pharmaceuticals inc. (nasdaq: acad) announced today that it has received a target action date of august 4, 2022 from the u.s. food and drug administration (fda) for its resubmitted supplemental new drug application (snda) for pimavanserin for the treatment of hallucinations and delusions associated with alzheimer's disease psychosis (adp). the fda's division of psychiatry has also advised the company that it is planning to hold an advisory committee meeting in
ACAD Ratings Summary
ACAD Quant Ranking